Rezolute (NASDAQ:RZLT) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS

by · The Markets Daily

Rezolute (NASDAQ:RZLT – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.14), Zacks reports.

Rezolute Trading Up 5.4 %

RZLT stock opened at $5.08 on Friday. The firm has a 50 day moving average of $4.62 and a 200-day moving average of $3.72. The company has a market cap of $203.89 million, a price-to-earnings ratio of -4.46 and a beta of 1.18. Rezolute has a 12-month low of $0.72 and a 12-month high of $6.10.

Wall Street Analyst Weigh In

RZLT has been the subject of several research reports. Craig Hallum started coverage on shares of Rezolute in a research report on Tuesday, June 4th. They issued a “buy” rating and a $14.00 price target for the company. JMP Securities reiterated a “market outperform” rating and set a $7.00 target price on shares of Rezolute in a research note on Friday. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Rezolute in a research report on Monday, September 9th. Guggenheim initiated coverage on Rezolute in a research note on Tuesday, August 27th. They set a “buy” rating and a $11.00 price objective for the company. Finally, BTIG Research lifted their target price on Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, September 10th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Rezolute has a consensus rating of “Buy” and a consensus target price of $11.57.

Check Out Our Latest Analysis on RZLT

Rezolute Company Profile

(Get Free Report)

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

See Also